{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T12:56:06Z","timestamp":1781528166683,"version":"3.54.1"},"reference-count":65,"publisher":"Oxford University Press (OUP)","issue":"2","funder":[{"name":"UK Health Security Agency"},{"name":"Oxford Expression Technologies or International Therapeutic Proteins Ltd"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,4,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Crimean\u2013Congo haemorrhagic fever virus (CCHFV) is a tick-borne pathogen that has a wide geographical range and has the potential to cause severe disease in those infected. There are no currently approved vaccines or therapeutics, so the development and assessment of new approaches are urgently required.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A polyclonal antibody-based therapeutic was developed based on immunization of sheep with the major glycoprotein antigens from CCHFV. Along with purified immunoglobulin G (IgG) from hyperimmune sera, fragmentation of the F(ab\u2019)2 region was also performed. The pharmacokinetic properties were assessed in mice, and efficacy was ascertained in a live CCHFV challenge model.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Candidate polyclonal antibody-based therapies were developed, demonstrating strong binding to the CCHFV envelope glycoprotein and neutralizing activity. The ovine whole IgG demonstrated stability post-delivery compared to a rapid reduction of the F(ab\u2019)2 fragment in the circulation. Efficacy testing when delivered either as a single dose before challenge or as daily dosing for 7\u00a0days starting on the day of challenge showed no demonstrable evidence of protection against infection.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Despite protection observed from vaccine candidates using the CCHFV glycoprotein as an antigen and administration of convalescent sera, the ovine antibody-based therapeutics did not confer similar efficacious effects in the mouse preclinical model.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/abt\/tbag017","type":"journal-article","created":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T11:34:10Z","timestamp":1776166450000},"page":"179-190","source":"Crossref","is-referenced-by-count":0,"title":["A hyperimmune ovine antibody-based therapeutic candidate against Crimean\u2013Congo haemorrhagic fever virus targeted to the Gn and Gc glycoproteins: high antibody levels with neutralization activity but lack of protective efficacy in a mouse model"],"prefix":"10.1093","volume":"9","author":[{"given":"Emma","family":"Kennedy","sequence":"first","affiliation":[{"name":"UK Health Security Agency (UKHSA), Porton Down , Salisbury, Wiltshire SP4 0JG ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Findlay-Wilson","sequence":"additional","affiliation":[{"name":"UK Health Security Agency (UKHSA), Porton Down , Salisbury, Wiltshire SP4 0JG ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Webster","sequence":"additional","affiliation":[{"name":"UK Health Security Agency (UKHSA), Porton Down , Salisbury, Wiltshire SP4 0JG ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annahita","family":"Rajabzadeh","sequence":"additional","affiliation":[{"name":"UK Health Security Agency (UKHSA), Porton Down , Salisbury, Wiltshire SP4 0JG ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Fotheringham","sequence":"additional","affiliation":[{"name":"UK Health Security Agency (UKHSA), Porton Down , Salisbury, Wiltshire SP4 0JG ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Easterbrook","sequence":"additional","affiliation":[{"name":"UK Health Security Agency (UKHSA), Porton Down , Salisbury, Wiltshire SP4 0JG ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Chambers","sequence":"additional","affiliation":[{"name":"Oxford Expression Technologies , Unit 9 Innovation Quarter, Oxford Technology Park, Kidlington OX5 1GN ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mine","family":"Aksular","sequence":"additional","affiliation":[{"name":"Oxford Expression Technologies , Unit 9 Innovation Quarter, Oxford Technology Park, Kidlington OX5 1GN ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Possee","sequence":"additional","affiliation":[{"name":"Oxford Expression Technologies , Unit 9 Innovation Quarter, Oxford Technology Park, Kidlington OX5 1GN ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Smith","sequence":"additional","affiliation":[{"name":"International Therapeutic Proteins Ltd , Longford, TAS 7301 ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neville","family":"Pope","sequence":"additional","affiliation":[{"name":"International Therapeutic Proteins Ltd , Goleigh Farm, Selborne, Hampshire GU34 3SE ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aled","family":"Griffiths","sequence":"additional","affiliation":[{"name":"SERB Pharmaceuticals , Blaenwaun, Ffostrasol, Llandysul, Ceredigion SA44 5JT ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrike","family":"Arnold","sequence":"additional","affiliation":[{"name":"UK Health Security Agency (UKHSA) , 61 Colindale Avenue, London NW9 5EQ ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Jackson","sequence":"additional","affiliation":[{"name":"UK Health Security Agency (UKHSA) , 61 Colindale Avenue, London NW9 5EQ ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"In\u00e9s","family":"Ruedas-Torres","sequence":"additional","affiliation":[{"name":"UK Health Security Agency (UKHSA), Porton Down , Salisbury, Wiltshire SP4 0JG ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco Javier","family":"Salguero","sequence":"additional","affiliation":[{"name":"UK Health Security Agency (UKHSA), Porton Down , Salisbury, Wiltshire SP4 0JG ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7378-8167","authenticated-orcid":false,"given":"Stuart","family":"Dowall","sequence":"additional","affiliation":[{"name":"UK Health Security Agency (UKHSA), Porton Down , Salisbury, Wiltshire SP4 0JG ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,4,15]]},"reference":[{"key":"2026061508282432200_ref1","doi-asserted-by":"publisher","first-page":"9","DOI":"10.3390\/microorganisms9091907","article-title":"Crimean-Congo Hemorrhagic fever virus in Asia, Africa and Europe","volume":"9","author":"Shahhosseini","year":"2021","journal-title":"Microorganisms"},{"key":"2026061508282432200_ref2","doi-asserted-by":"publisher","first-page":"7771431","DOI":"10.1155\/tbed\/7771431","article-title":"Hyalomma marginatum in Europe: the past, current status, and future challenges-a systematic review","volume":"2025","author":"Celina","year":"2025","journal-title":"Transbound Emerg Dis"},{"key":"2026061508282432200_ref3","doi-asserted-by":"publisher","first-page":"101429","DOI":"10.1016\/j.cimid.2020.101429","article-title":"New aspects about Crimean-Congo hemorrhagic fever (CCHF) cases and associated fatality trends: a global systematic review and meta-analysis","volume":"69","author":"Nasirian","year":"2020","journal-title":"Comp Immunol Microbiol Infect Dis"},{"key":"2026061508282432200_ref4","doi-asserted-by":"publisher","first-page":"6015","DOI":"10.1016\/j.vaccine.2017.05.031","article-title":"Development of vaccines against Crimean-Congo haemorrhagic fever virus","volume":"35","author":"Dowall","year":"2017","journal-title":"Vaccine"},{"key":"2026061508282432200_ref5","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1038\/s41579-023-00871-9","article-title":"Crimean-Congo haemorrhagic fever virus","volume":"21","author":"Hawman","year":"2023","journal-title":"Nat Rev Microbiol"},{"key":"2026061508282432200_ref6","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.antiviral.2018.09.009","article-title":"The WHO R&D blueprint: 2018 review of emerging infectious diseases requiring urgent research and development efforts","volume":"159","author":"Mehand","year":"2018","journal-title":"Antiviral Res"},{"key":"2026061508282432200_ref7","doi-asserted-by":"publisher","first-page":"199409","DOI":"10.1016\/j.virusres.2024.199409","article-title":"Convalescent human plasma candidate reference materials protect against Crimean-Congo haemorrhagic fever virus (CCHFV) challenge in an A129 mouse model","volume":"346","author":"Kempster","year":"2024","journal-title":"Virus Res"},{"key":"2026061508282432200_ref8","doi-asserted-by":"publisher","first-page":"439","DOI":"10.7883\/yoken.64.439","article-title":"Prompt administration of Crimean-Congo hemorrhagic fever (CCHF) virus hyperimmunoglobulin in patients diagnosed with CCHF and viral load monitorization by reverse transcriptase-PCR","volume":"64","author":"Kubar","year":"2011","journal-title":"Jpn J Infect Dis"},{"key":"2026061508282432200_ref9","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1016\/0140-6736(90)90906-L","article-title":"Specific intravenous immunoglobulin for Crimean-Congo haemorrhagic fever","volume":"335","author":"Vassilenko","year":"1990","journal-title":"Lancet"},{"key":"2026061508282432200_ref10","doi-asserted-by":"publisher","first-page":"1486","DOI":"10.7150\/ijbs.59149","article-title":"Development and application of therapeutic antibodies against COVID-19","volume":"17","author":"Ning","year":"2021","journal-title":"Int J Biol Sci"},{"key":"2026061508282432200_ref11","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.cimid.2007.11.004","article-title":"Ovine anti-rabies antibody production and evaluation","volume":"32","author":"Redwan el","year":"2009","journal-title":"Comp Immunol Microbiol Infect Dis"},{"key":"2026061508282432200_ref12","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.cimid.2005.01.001","article-title":"Production and purification of ovine anti-tetanus antibody","volume":"28","author":"Redwan el","year":"2005","journal-title":"Comp Immunol Microbiol Infect Dis"},{"key":"2026061508282432200_ref13","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1093\/infdis\/jiv565","article-title":"Development of a cost-effective ovine polyclonal antibody-based product, EBOTAb, to treat Ebola virus infection","volume":"213","author":"Dowall","year":"2016","journal-title":"J Infect Dis"},{"key":"2026061508282432200_ref14","doi-asserted-by":"publisher","first-page":"30497","DOI":"10.1038\/srep30497","article-title":"Post-exposure treatment of Ebola virus disease in guinea pigs using EBOTAb, an ovine antibody-based therapeutic","volume":"6","author":"Dowall","year":"2016","journal-title":"Sci Rep"},{"key":"2026061508282432200_ref15","doi-asserted-by":"publisher","first-page":"4099","DOI":"10.1038\/s41598-017-03910-7","article-title":"Post-exposure treatment of non-human primates lethally infected with Ebola virus with EBOTAb, a purified ovine IgG product","volume":"7","author":"Dowall","year":"2017","journal-title":"Sci Rep"},{"key":"2026061508282432200_ref16","doi-asserted-by":"publisher","first-page":"105332","DOI":"10.1016\/j.antiviral.2022.105332","article-title":"Development of a cost-effective ovine antibody-based therapy against SARS-CoV-2 infection and contribution of antibodies specific to the spike subunit proteins","volume":"203","author":"Findlay-Wilson","year":"2022","journal-title":"Antiviral Res"},{"key":"2026061508282432200_ref17","doi-asserted-by":"publisher","first-page":"13912","DOI":"10.1038\/s41598-023-40277-4","article-title":"Refinement of an ovine-based immunoglobulin therapy against SARS-CoV-2, with comparison of whole IgG versus F(ab')(2) fragments","volume":"13","author":"Findlay-Wilson","year":"2023","journal-title":"Sci Rep"},{"key":"2026061508282432200_ref18","doi-asserted-by":"publisher","first-page":"106","DOI":"10.3390\/v8040106","article-title":"Molecular insights into Crimean-Congo hemorrhagic fever virus","volume":"8","author":"Zivcec","year":"2016","journal-title":"Viruses"},{"key":"2026061508282432200_ref19","doi-asserted-by":"publisher","first-page":"7263","DOI":"10.1128\/JVI.76.14.7263-7275.2002","article-title":"Characterization of the glycoproteins of Crimean-Congo hemorrhagic fever virus","volume":"76","author":"Sanchez","year":"2002","journal-title":"J Virol"},{"key":"2026061508282432200_ref20","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1038\/s41541-025-01164-3","article-title":"Single dose VSV-based vaccine protects mice against lethal heterologous Crimean-Congo hemorrhagic fever virus challenge","volume":"10","author":"Tipih","year":"2025","journal-title":"NPJ Vaccines"},{"key":"2026061508282432200_ref21","doi-asserted-by":"publisher","first-page":"7755","DOI":"10.1038\/s41598-019-44210-6","article-title":"Vesicular stomatitis virus-based vaccine protects mice against Crimean-Congo Hemorrhagic fever","volume":"9","author":"Rodriguez","year":"2019","journal-title":"Sci Rep"},{"key":"2026061508282432200_ref22","doi-asserted-by":"publisher","first-page":"e91516","DOI":"10.1371\/journal.pone.0091516","article-title":"A novel vaccine against Crimean-Congo haemorrhagic fever protects 100% of animals against lethal challenge in a mouse model","volume":"9","author":"Buttigieg","year":"2014","journal-title":"PloS One"},{"key":"2026061508282432200_ref23","doi-asserted-by":"publisher","first-page":"104523","DOI":"10.1016\/j.ebiom.2023.104523","article-title":"Adenoviral vectored vaccination protects against Crimean-Congo haemorrhagic fever disease in a lethal challenge model","volume":"90","author":"Saunders","year":"2023","journal-title":"EBioMedicine"},{"key":"2026061508282432200_ref24","doi-asserted-by":"publisher","first-page":"e0005908","DOI":"10.1371\/journal.pntd.0005908","article-title":"A DNA vaccine for Crimean-Congo hemorrhagic fever protects against disease and death in two lethal mouse models","volume":"11","author":"Garrison","year":"2017","journal-title":"PLoS Negl Trop Dis"},{"key":"2026061508282432200_ref25","doi-asserted-by":"publisher","first-page":"e0156821","DOI":"10.1128\/jvi.01568-21","article-title":"Nucleoside-modified mRNA vaccines protect IFNAR(\u2212\/\u2212) mice against Crimean-Congo hemorrhagic fever virus infection","volume":"96","author":"Appelberg","year":"2022","journal-title":"J Virol"},{"key":"2026061508282432200_ref26","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1146\/annurev.biochem.73.011303.073752","article-title":"Roles of N-linked glycans in the endoplasmic reticulum","volume":"73","author":"Helenius","year":"2004","journal-title":"Annu Rev Biochem"},{"key":"2026061508282432200_ref27","doi-asserted-by":"publisher","first-page":"5414","DOI":"10.1128\/JVI.78.10.5414-5422.2004","article-title":"Analysis of N-linked glycosylation of hantaan virus glycoproteins and the role of oligosaccharide side chains in protein folding and intracellular trafficking","volume":"78","author":"Shi","year":"2004","journal-title":"J Virol"},{"key":"2026061508282432200_ref28","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1126\/science.288.5464.331","article-title":"Chaperone selection during glycoprotein translocation into the endoplasmic reticulum","volume":"288","author":"Molinari","year":"2000","journal-title":"Science"},{"key":"2026061508282432200_ref29","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/S0014-5793(00)01665-3","article-title":"Lectins and traffic in the secretory pathway","volume":"476","author":"Hauri","year":"2000","journal-title":"FEBS Lett"},{"key":"2026061508282432200_ref30","doi-asserted-by":"publisher","first-page":"13262","DOI":"10.1128\/JVI.79.21.13262-13274.2005","article-title":"N-linked glycosylation of west nile virus envelope proteins influences particle assembly and infectivity","volume":"79","author":"Hanna","year":"2005","journal-title":"J Virol"},{"key":"2026061508282432200_ref31","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1016\/j.virol.2006.11.023","article-title":"N-linked glycosylation of Gn (but not Gc) is important for Crimean Congo hemorrhagic fever virus glycoprotein localization and transport","volume":"361","author":"Erickson","year":"2007","journal-title":"Virology"},{"key":"2026061508282432200_ref32","doi-asserted-by":"publisher","first-page":"197865","DOI":"10.1016\/j.virusres.2020.197865","article-title":"Post-translational modification of baculovirus-encoded proteins","volume":"279","author":"Chen","year":"2020","journal-title":"Virus Res"},{"key":"2026061508282432200_ref33","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1007\/10_2018_61","article-title":"Glycobiotechnology of the insect cell-baculovirus expression system technology","volume":"175","author":"Palomares","year":"2021","journal-title":"Adv Biochem Eng Biotechnol"},{"key":"2026061508282432200_ref34","doi-asserted-by":"publisher","first-page":"5957","DOI":"10.1128\/JVI.03691-14","article-title":"A virus-like particle system identifies the endonuclease domain of Crimean-Congo hemorrhagic fever virus","volume":"89","author":"Devignot","year":"2015","journal-title":"J Virol"},{"key":"2026061508282432200_ref35","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1186\/s12896-024-00885-y","article-title":"Purification and characterization of soluble recombinant Crimean-Congo hemorrhagic fever virus glycoprotein Gc expressed in mammalian 293F cells","volume":"24","author":"Makoah","year":"2024","journal-title":"BMC Biotechnol"},{"key":"2026061508282432200_ref36","doi-asserted-by":"publisher","first-page":"257","DOI":"10.5681\/apb.2013.042","article-title":"Gene expression in mammalian cells and its applications","volume":"3","author":"Khan","year":"2013","journal-title":"Adv Pharm Bull"},{"key":"2026061508282432200_ref37","doi-asserted-by":"publisher","first-page":"1951","DOI":"10.1007\/s00705-017-3315-3","article-title":"Expression and characterization of codon-optimized Crimean-Congo hemorrhagic fever virus Gn glycoprotein in insect cells","volume":"162","author":"Rahpeyma","year":"2017","journal-title":"Arch Virol"},{"key":"2026061508282432200_ref38","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1089\/vbz.2015.1855","article-title":"Crimean-Congo Hemorrhagic fever virus subunit vaccines induce high levels of neutralizing antibodies but No protection in STAT1 knockout mice","volume":"15","author":"Kortekaas","year":"2015","journal-title":"Vector Borne Zoonotic Dis"},{"key":"2026061508282432200_ref39","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1038\/s41564-020-00815-6","article-title":"A DNA-based vaccine protects against Crimean-Congo haemorrhagic fever virus disease in a cynomolgus macaque model","volume":"6","author":"Hawman","year":"2021","journal-title":"Nat Microbiol"},{"key":"2026061508282432200_ref40","doi-asserted-by":"publisher","first-page":"e0156637","DOI":"10.1371\/journal.pone.0156637","article-title":"Protective effects of a modified vaccinia Ankara-based vaccine candidate against Crimean-Congo haemorrhagic fever virus require both cellular and humoral responses","volume":"11","author":"Dowall","year":"2016","journal-title":"PLoS One"},{"key":"2026061508282432200_ref41","doi-asserted-by":"crossref","first-page":"e913","DOI":"10.1016\/j.cell.2018.07.033","article-title":"Systematic analysis of monoclonal antibodies against Ebola virus GP defines features that contribute to protection","volume":"174","author":"Saphire","year":"2018","journal-title":"Cell"},{"key":"2026061508282432200_ref42","doi-asserted-by":"publisher","first-page":"4223","DOI":"10.1038\/s41467-018-06741-w","article-title":"Non-neutralizing antibodies elicited by recombinant Lassa-rabies vaccine are critical for protection against Lassa fever","volume":"9","author":"Abreu-Mota","year":"2018","journal-title":"Nat Commun"},{"key":"2026061508282432200_ref43","doi-asserted-by":"publisher","first-page":"e2200065119","DOI":"10.1073\/pnas.2200065119","article-title":"A recombinant VSV-vectored vaccine rapidly protects nonhuman primates against lethal Nipah virus disease","volume":"119","author":"Foster","year":"2022","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2026061508282432200_ref44","doi-asserted-by":"publisher","first-page":"108962","DOI":"10.1016\/j.celrep.2021.108962","article-title":"The mechanistic basis of protection by non-neutralizing anti-alphavirus antibodies","volume":"35","author":"Earnest","year":"2021","journal-title":"Cell Rep"},{"key":"2026061508282432200_ref45","doi-asserted-by":"publisher","first-page":"eaaw9535","DOI":"10.1126\/sciadv.aaw9535","article-title":"GP38-targeting monoclonal antibodies protect adult mice against lethal Crimean-Congo hemorrhagic fever virus infection","volume":"5","author":"Golden","year":"2019","journal-title":"Sci Adv"},{"key":"2026061508282432200_ref46","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.02005-19","article-title":"Structure and characterization of Crimean-Congo hemorrhagic fever virus GP38","volume":"94","author":"Mishra","year":"2020","journal-title":"J Virol"},{"key":"2026061508282432200_ref47","doi-asserted-by":"publisher","first-page":"eady7328","DOI":"10.1126\/sciimmunol.ady7328","article-title":"Cross-species cellular mapping and humanization of Fcgamma receptors to advance antibody modeling","volume":"11","author":"Van Damme","year":"2026","journal-title":"Sci Immunol"},{"key":"2026061508282432200_ref48","doi-asserted-by":"publisher","first-page":"9236","DOI":"10.1038\/s41467-024-53362-7","article-title":"Antibodies targeting the Crimean-Congo Hemorrhagic fever virus nucleoprotein protect via TRIM21","volume":"15","author":"Leventhal","year":"2024","journal-title":"Nat Commun"},{"key":"2026061508282432200_ref49","doi-asserted-by":"publisher","first-page":"1722","DOI":"10.1038\/s41467-024-46110-4","article-title":"Nucleocapsid protein-specific monoclonal antibodies protect mice against Crimean-Congo hemorrhagic fever virus","volume":"15","author":"Garrison","year":"2024","journal-title":"Nat Commun"},{"key":"2026061508282432200_ref50","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.antiviral.2013.07.006","article-title":"Crimean-Congo hemorrhagic fever: history, epidemiology, pathogenesis, clinical syndrome and genetic diversity","volume":"100","author":"Bente","year":"2013","journal-title":"Antiviral Res"},{"key":"2026061508282432200_ref51","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1128\/JVI.80.1.514-525.2006","article-title":"Crimean-Congo hemorrhagic fever virus glycoprotein precursor is cleaved by Furin-like and SKI-1 proteases to generate a novel 38-kilodalton glycoprotein","volume":"80","author":"Sanchez","year":"2006","journal-title":"J Virol"},{"key":"2026061508282432200_ref52","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/j.cell.2024.11.008","article-title":"Engineering and structures of Crimean-Congo hemorrhagic fever virus glycoprotein complexes","volume":"188","author":"McFadden","year":"2025","journal-title":"Cell"},{"key":"2026061508282432200_ref53","doi-asserted-by":"publisher","first-page":"eadq5928","DOI":"10.1126\/scitranslmed.adq5928","article-title":"Antibodies targeting Crimean-Congo hemorrhagic fever virus GP38 limit vascular leak and viral spread","volume":"17","author":"Pahmeier","year":"2025","journal-title":"Sci Transl Med"},{"key":"2026061508282432200_ref54","doi-asserted-by":"publisher","first-page":"7298","DOI":"10.1038\/s41467-022-34923-0","article-title":"Structural characterization of protective non-neutralizing antibodies targeting Crimean-Congo hemorrhagic fever virus","volume":"13","author":"Durie","year":"2022","journal-title":"Nat Commun"},{"key":"2026061508282432200_ref55","doi-asserted-by":"publisher","first-page":"114502","DOI":"10.1016\/j.celrep.2024.114502","article-title":"Crimean-Congo hemorrhagic fever survivors elicit protective non-neutralizing antibodies that target 11 overlapping regions on glycoprotein GP38","volume":"43","author":"Shin","year":"2024","journal-title":"Cell Rep"},{"key":"2026061508282432200_ref56","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1038\/s41541-021-00293-9","article-title":"A CCHFV DNA vaccine protects against heterologous challenge and establishes GP38 as immunorelevant in mice","volume":"6","author":"Suschak","year":"2021","journal-title":"NPJ Vaccines"},{"key":"2026061508282432200_ref57","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1038\/s41541-023-00663-5","article-title":"GP38 as a vaccine target for Crimean-Congo hemorrhagic fever virus","volume":"8","author":"Scher","year":"2023","journal-title":"NPJ Vaccines"},{"key":"2026061508282432200_ref58","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1038\/s41541-024-00931-y","article-title":"Crimean Congo hemorrhagic fever virus nucleoprotein and GP38 subunit vaccine combination prevents morbidity in mice","volume":"9","author":"Karaaslan","year":"2024","journal-title":"NPJ Vaccines"},{"key":"2026061508282432200_ref59","doi-asserted-by":"publisher","first-page":"6152","DOI":"10.1128\/JVI.79.10.6152-6161.2005","article-title":"Cellular localization and antigenic characterization of Crimean-Congo hemorrhagic fever virus glycoproteins","volume":"79","author":"Bertolotti-Ciarlet","year":"2005","journal-title":"J Virol"},{"key":"2026061508282432200_ref60","doi-asserted-by":"publisher","first-page":"3486","DOI":"10.1016\/j.cell.2021.05.001","article-title":"Protective neutralizing antibodies from human survivors of Crimean-Congo hemorrhagic fever","volume":"184","author":"Fels","year":"2021","journal-title":"Cell"},{"key":"2026061508282432200_ref61","doi-asserted-by":"publisher","first-page":"e0320224","DOI":"10.1128\/mbio.03202-24","article-title":"Avidity and variable domain spacing strongly influence the therapeutic potency of bispecific antibodies against Crimean-Congo hemorrhagic fever virus","volume":"16","author":"Wang","year":"2025","journal-title":"mBio"},{"key":"2026061508282432200_ref62","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1016\/j.virusres.2009.11.009","article-title":"The complete genome analysis of Crimean-Congo hemorrhagic fever virus isolated in Turkey","volume":"147","author":"Ozdarendeli","year":"2010","journal-title":"Virus Res"},{"key":"2026061508282432200_ref63","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/2191-219X-1-1","article-title":"In vitro and In vivo pre-clinical analysis of a F(ab')(2) fragment of panitumumab for molecular imaging and therapy of HER1 positive cancers","volume":"1","author":"Wong","year":"2011","journal-title":"EJNMMI Res"},{"key":"2026061508282432200_ref64","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1385\/1-59259-075-6:115","article-title":"Effect of dose, molecular size, and binding affinity on uptake of antibodies","volume":"25","author":"Thomas","year":"2000","journal-title":"Methods Mol Med"},{"key":"2026061508282432200_ref65","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1016\/j.str.2004.02.011","article-title":"Structure and flexibility of individual immunoglobulin G molecules in solution","volume":"12","author":"Sandin","year":"2004","journal-title":"Structure"}],"container-title":["Antibody Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/abt\/advance-article-pdf\/doi\/10.1093\/abt\/tbag017\/68085159\/tbag017.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/abt\/article-pdf\/9\/2\/179\/68085159\/tbag017.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/abt\/article-pdf\/9\/2\/179\/68085159\/tbag017.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T12:28:28Z","timestamp":1781526508000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/abt\/article\/9\/2\/179\/8654272"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,1]]},"references-count":65,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,4,1]]}},"URL":"https:\/\/doi.org\/10.1093\/abt\/tbag017","relation":{},"ISSN":["2516-4236"],"issn-type":[{"value":"2516-4236","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,4]]},"published":{"date-parts":[[2026,4,1]]}}}